Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review.

Fiche publication

Date publication

septembre 2026

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MAYEUR Didier

Tous les auteurs :
Scotté F, Lustberg M, Aapro M, Ben Abid F, Bošnjak S, Ruhlmann CH, Klastersky J, Mayeur D, Rugo HS, Cooksley T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42790204

Résumé

Although multiple antibody-drug conjugates (ADCs) have demonstrated sufficient efficacy and safety to warrant their approval, many patients require supportive treatment to reduce the severity of ADC-associated toxicities. Clinical guidelines recommend the use of granulocyte colony-stimulating factors (G‑CSFs), such as filgrastim, lenograstim, and long-acting pegfilgrastim, to reduce the duration and severity of chemotherapy-induced neutropenia and the risk of febrile neutropenia (FN).